公开(公告)号：US20240216401A1

公开(公告)日：2024-07-04

申请号：US18288215

申请日：2021-04-28

申请人： OBI Pharma, Inc.

发明人： Ming-Tain LAI ,  Wan-Fen LI ,  Chun-Chung Wang ,  Lu-Tzu Chen

IPC分类号： A61K31/675 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K31/675 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

摘要： A pharmaceutical composition, including a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-N ethyl-N,N′-bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

公开(公告)号：US20240084040A1

公开(公告)日：2024-03-14

申请号：US18264563

申请日：2022-02-09

申请人： OBI PHARMA, INC.

发明人： Jiann-Shiun LAI ,  Hui-Wen CHANG ,  Yin-Chieh KUO ,  Chi-Sheng HSIA ,  Woan Eng CHAN ,  Ming-Tain LAI

IPC分类号： C07K16/46 ,  A61P35/00

CPC分类号： C07K16/468 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

摘要： The present invention provides antibody or the antigen-binding portion thereof bind to carbohydrate antigen, such as Globo series antigens (e.g. Globo H, SSEA-4 or SSEA-3). Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

公开(公告)号：US20240139301A1

公开(公告)日：2024-05-02

申请号：US18253576

申请日：2021-11-19

申请人： OBI Pharma, Inc.

发明人： Ming-Tain LAI ,  Cheng-Der Tony YU ,  I-Ju CHEN ,  Wei-Han LEE ,  Chueh-Hao YANG ,  Chun-Yen TSAO ,  Chang-Lin HSIEH ,  Chien-Chih OU ,  Chen-En TSAI

IPC分类号： A61K39/00 ,  A61K45/06 ,  A61K47/64 ,  A61P35/00

CPC分类号： A61K39/001173 ,  A61K45/06 ,  A61K47/646 ,  A61P35/00 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/86

摘要： The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

公开(公告)号：US20210093733A1

公开(公告)日：2021-04-01

申请号：US17006881

申请日：2020-08-30

申请人： OBI Pharma, Inc.

发明人： Michael Nientse CHANG ,  Ming-Tain LAI ,  Jiann-Shiun LAI ,  Yi-Chien TSAI ,  I-Ju CHEN ,  Wan-Fen LI ,  Kai-Chuan CHEN ,  Teng-Yi HUANG ,  Shu-Yi LIN

IPC分类号： A61K47/68 ,  C07K16/18 ,  A61K45/06 ,  A61P35/00

摘要： Antibody drug conjugates (ADC's) comprising a drug moiety/payload conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.